Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-randomized, Phase I Study of Allogeneic Placenta Derived Mesenchymal Stem Cells in Patients With Secondary-Progressive Multiple Sclerosis (SPMS),

NCT06360861 is registered in ClinicalTrials.gov with Tehran University of Medical Sciences as lead sponsor.

NCT NCT06360861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06360861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-randomized, Phase I Study of Allogeneic Placenta Derived Mesenchymal Stem Cells in Patients With Secondary-Progressive Multiple Sclerosis (SPMS),
Lead sponsor
Tehran University of Medical Sciences
Phase
Phase 1
Overall status
Completed
Start date
July 23, 2019
Completion date
March 6, 2024
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mesenchymal stem cells, multiple sclerosis, secondary-progressive multiple sclerosis